Toggle navigation
Goals &
Objectives
Distinguished
Faculty
Education &
Resources
Contact
Us
Toggle navigation
Goals & Objectives
Distinguished Faculty
Education & Resources▼
CME Programs
Find a Clinician
SpeakerReady
Polling Questions
Conference Calendar
Refer a Colleague
Literature
Resources
Contact
Polling Questions
< All Questions
According to the webcast:
with Sharon J. Parish, MD , IF, NCMP
In their briefing document, Division Summary, phase 3 placebo-controlled trials, on flibanserin, depression, and SS/RIs, the FDA states:
Combination of flibanserin with SS/NRI did not exacerbated dizziness and insomnia
Flibanserin did not exacerbate depression or anxiety in patients taking SSRI or SNRI medication (in dedicated SSRI study)
Flibanserin is contraindicated in patients on SSRI/SNRI medication
Adverse events affected over 25% of participating patients
Your answers are confidential and will be used for educational purposes only.
Submit